Pharnext
15.7.2021 18:16:33 CEST | ACCESS Newswire | Press release
PARIS, FRANCE / ACCESSWIRE / July 15, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the "Company"), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY(TM) platform, today announces its Board of Directors has appointed Piers Morgan as a new, independent, non-executive member following a comprehensive search and selection process. This cooptation will be submitted to the approval of the next shareholders meeting of Pharnext. In addition, based on his strong financial background as CFO of several biotech companies, Piers Morgan will also chair the Audit Committee of the Company.
Piers Morgan has over 20 years of experience in senior biotech roles, principally as Chief Financial Officer. He has led Nasdaq Initial Public Offerings and Follow-on Financings for COMPASS Pathways, raising more than $300m; for Amsterdam-based biotechnology company uniQure, which he co-founded; and Verona Pharma, that dual-listed from London's AIM exchange. Piers Morgan was also CEO of C4X Discovery, a UK biotechnology company, which went public on AIM under his leadership.
Piers Morgan received an MA in Law and Management Studies from the University of Cambridge and qualified as a Chartered Accountant with PwC in London. He spent almost 10 years advising on M&A and financings for small and mid-cap companies with Close Brothers and Ernst & Young. He currently serves as a Non-Executive Director at Ikarovec Ltd and was previously the same at Quethera (sold to Astellas for £85 million).
Michel de Rosen, Chairman of Pharnext's Board of Directors,said: "We thank Jean Combalbert for his precious contribution during the time he served on our board. I'm honored and thrilled to welcome Piers to our Board of Directors as we advance our pivotal Phase III clinical study, the PREMIER trial, of PXT3003 in Charcot-Marie-Tooth disease type 1A. We have recently enrolled our first US and European patients in this trial and our lead treatment candidate remains the main focus of the Company's resources. Piers Morgan's wealth of financial experience will be highly valuable when we explore new financing opportunities in the future to support the growth of our company."
Piers Morgan, new Board Member of Pharnext,said: "PXT3003, Pharnext's lead drug candidate, has the potential to address serious unmet medical need in the CMT space. I am pleased to join the Board and work alongside its members and the management team to support the Company on its important journey to bring new therapeutic solutions for patients suffering from severe diseases with no satisfactory alternatives such as CMT1A, and to create more value for its shareholders."
Piers Morgan is replacing Jean Combalbert, who is resigning for personal reasons, for the remainder of the latter's term, which runs until the annual shareholder's meeting called to approve the 2022 financial statements.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A ('CMT1A') and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer's disease and will be advanced through partnerships. Pharnext has developed a new drug discovery paradigm based on big genomics data and artificial intelligence: PLEOTHERAPY(TM). Pharnext identifies and develops synergic combinations of drugs called PLEODRUG(TM). More information can be found at www.pharnext.com .
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
Disclaimer
This press release contains certain forward-looking statements concerning Pharnext and its business, including in respect of timing of and prospects for clinical trials and regulatory submissions of the Company's product candidates as well as a potential financing transaction, the use of proceeds therefrom and cash runway. Such forward-looking statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in Pharnext's URD approved by the AMF on November 9, 2020 under number N° R. 20-029 as well as in its annual periodic management reports and press releases (copies of which are available on www.pharnext.com) and to the development of economic conditions, financial markets and the markets in which Pharnext operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or not currently considered material by Pharnext. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Pharnext to be materially different from such forward-looking statements. Pharnext disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Pharnext shares in any country, including the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer that will contain detailed information about the Company and management, as well as financial statements.
Contacts:
David Horn Solomon
Chief Executive Officer
contact@pharnext.com
+33 (0)1 41 09 22 30
Media Relations (International)
Consilium Strategic Communications
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison
pharnext@consilium-comms.com
Financial Communication (Europe)
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 (0)6 21 10 49 24
Media Relations (France)
Ulysse Communication
Bruno Arabian
barabian@ulysse-communication.com
+33 (0)6 87 88 47 26
+33 (0)1 81 70 96 30
SOURCE: Pharnext SA
To view this piece of content from eqs-cockpit.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/655711/Piers-Morgan-Joins-Pharnexts-Board-of-Directors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TIS, EuroFinance Study Finds Corporate Treasurers Actively Evaluating AI, But Hesitant to Adopt It28.7.2026 15:00:00 CEST | Press release
The EuroFinance Deep Dive, supported by Treasury Intelligence Solutions (TIS), interviewed and surveyed corporate treasury leaders, finding that while they see AI as a powerful tool for cash forecasting, multiple concerns are deterring them from adopting it - for now. BERLIN, DE / ACCESS Newswire / July 28, 2026 / Treasury Intelligence Solutions (TIS), a best-in-class solution for payments and cash management, partnered with the research and trade association EuroFinance, in a research initiative that discovered nearly half of leading corporate finance teams are considering the use of artificial intelligence in cash forecasting - but just as many are holding off because of concerns over the technology. The EuroFinance Deep Dive, AI in Treasury: Accuracy, Intelligence and the Future of Cash Forecasting, brings together proprietary research, survey data, and perspectives from treasury leaders at Microsoft, Siemens Energy and other companies to assess where AI is creating value and where
CHAR Tech Provide Update on GazoTech's Bio-Methane Provence Project28.7.2026 14:00:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 28, 2026 / (TSXV:YES)(OTC PINK:CTRNF)(FSE:68K) GazoTech's lead project, Bio-Méthane Provence ("BMP"), an industrial-scale HTP project in France developed under the CHAR Tech / GazoTech collaboration, has successfully concluded its CNDP-supervised voluntary public consultation, with a clear majority of opinions supporting the project BMP is redeveloping the site of a former 600 MW coal-fired power plant in Gardanne, France, converting legacy fossil infrastructure into renewable energy production Once operational, BMP is expected to process 115,000 tonnes of recovered wood annually, producing 230 GWh (828,000 GJ) of RNG plus 12,000 tonnes of biocarbon, targeting commercial operations in H2 2029 CHAR Technologies Ltd. ("CHAR Tech" or "the Company"), a leader in sustainable biomass energy solutions, today provided an update on the Bio-Méthane Provence ("BMP") project in Gardanne, France, an industrial-scale High-Temperature Pyrolysis ("HTP") project bei
Giatec Completes Its First International MixPilot Fleet Roll-Out with Heidelberg Materials UK28.7.2026 11:00:00 CEST | Press release
Following a successful trial validating MixPilot in a new market, across an expanded range of truck types and slump measurement standards, Giatec and Heidelberg Materials sign a binding agreement to scale MixPilot across the Heidelberg Materials UK fleet. OTTAWA, ON / ACCESS Newswire / July 28, 2026 / Giatec, a global leader in digital concrete technology platforms, today announced that Giatec and Heidelberg Materials, one of the world's largest integrated manufacturers of heavy building materials and solutions, have scaled MixPilot across Heidelberg Materials' UK concrete operations. MixPilot was selected on the strength of two factors: superior slump accuracy, validated against other systems under real operating conditions, and driver adoption, with the superior app interface becoming a key catalyst for fleet-wide buy-in. "MixPilot delivered something simple but rare: data our team could trust from day one," said Fabrice Arriordaz, Regional Operations Manager, North Concrete, Heidelb
LiberNovo Omni SE, Omni Pro and Maxis Enter Final Week of Early Bird Launch Pricing24.7.2026 09:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / July 24, 2026 / Seven days is what remains of LiberNovo's 2026 launch pricing. Across the EU and UK, Omni SE, Omni Pro, and the Maxis series hold their early bird prices until July 31, and the window closes there. The whole lineup is built around dynamic ergonomics: the support system links the neck support, backrest, armrests, and seat, so everything moves together as you shift, lean, and recline. The chair follows the movement; you get on with the work. A quick way to choose Omni SE: the simplest build in the lineup. No motor and no battery; you set the lumbar depth by hand and the automatic support does the rest. Solid dynamic ergonomics at the friendlier price. Better Comfort, Simplified. Omni Pro: the premium chair in the lineup. Motorized lumbar adjustment and the OmniStretch guided back stretch at the press of a button, plus Active Airflow ventilation built into the seat for long days and warm rooms, an aluminum base, and Danish Gabriel fabric.
2026 Fields Medals Awarded to Four of World's Top Mathematicians23.7.2026 16:45:00 CEST | Press release
The award, nicknamed the Nobel Prize of mathematics, recognizes outstanding achievement - and the promise of future achievement - by mathematicians under 40. PHILADELPHIA, PA / ACCESS Newswire / July 23, 2026 / During today's opening ceremony at the International Congress of Mathematicians (ICM) in Philadelphia, the International Mathematical Union (IMU) announced the recipients of the 2026 Fields Medals. This year's prizes went to four of the world's top mathematicians: Chinese mathematician Yu Deng of the University of Chicago; American mathematician John Pardon of Stony Brook University in New York; Canadian mathematician Jacob Tsimerman of the University of Toronto; and Chinese mathematician Hong Wang of New York University and France's Institut des Hautes Études Scientifiques (IHES). The Fields Medal is often described as the Nobel Prize of mathematics due to its prestige. Awarded every four years to two to four mathematicians under the age of 40, the medal recognizes outstanding
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom